A phase II study of chronic low dose of interleukin-2 (IL2) and α-interferon (IFN-α) in metastatic renal cell carcinoma (MRCC)

被引：0
|
作者：
Cengarle, R
Buzio, C
Pavone, L
Santi, R
Todeschini, R
Caminiti, C
Porta, C
Bidin, L
Frassoldati, A
Contu, A
Passalacqua, R
机构：
[1] Div Oncol, Parma, Italy
[2] Div Oncol, Pavia, Italy
[3] Div Oncol, Modena, Italy
[4] Div Oncol, Sassari, Italy
[5] Div Oncol, Piacenza, Italy
[6] Univ Parma, Nephrol Ist, I-43100 Parma, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D9
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [1] A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    Garcia, J. A.
    Rini, B. I.
    Mekhail, T.
    Triozzi, P.
    Elson, P.
    Nemec, C.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Original regimen of subcutaneous interleukin 2 (IL2) and interferon alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC) ineligible to receive intravenous (iv) IL2
    Escudier, B
    Rossi, JF
    Ravaud, A
    Savary, J
    Pignard, K
    Negrier, S
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 470 - 470
  • [3] Results of the first line biochemotherapy with interleukin-2 (IL2), interferon (IFN) and 5-FU and second line biochemotherapy with retinoids and interferon in metastatic renal cell carcinoma (MRCC)
    Zemanova, M
    Petruzelka, L
    ANNALS OF ONCOLOGY, 1998, 9 : 62 - 62
  • [4] Interleukin-2 (IL-2), interferon-α (IFN-α), 5-fluorouracil (5-FU) and vinblastine (VBL) for treatment of metastatic renal cell carcinoma (MRCC).: A prospective phase II study.
    Rubinov, R
    Gez, E
    Haim, N
    Kuten, A
    Meritick, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 424S - 424S
  • [5] Low-dose interleukin-2 (IL-2) in combination with interferon-A (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma (MRCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 286 - 286
  • [6] A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma
    A. Piga
    Paolo Giordani
    Agata Quattrone
    Marco Giulioni
    Giorgio De Signoribus
    Stefania Antognoli
    Riccardo Cellerino
    Cancer Immunology, Immunotherapy, 1997, 44 : 348 - 351
  • [7] Interleukin-2 (IL-2) chrono-infusion (CHI) in metastatic renal cell carcinoma (mRCC): A phase I/II study.
    Lo Re, Giovanni
    Santeufemia, Davide Adriano
    Lenardon, Oliviero
    Talamini, Renato
    Del Conte, Alessandro
    Marus, Wally
    Nicolosi, Gianluigi
    Mancinelli, Paolo
    Tumolo, Salvatore
    Garbeglio, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [8] Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial
    Buti, S.
    Lazzarelli, S.
    Simonelli, C.
    Venturini, S.
    Spazzapan, S.
    Lo Re, G.
    Mattioli, R.
    Chiesa, M. Dalla
    Brighenti, M.
    Passalacqua, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma
    Piga, A
    Giordani, P
    Quattrone, A
    Giulioni, M
    DeSignoribus, G
    Antognoli, S
    Cellerino, R
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (06) : 348 - 351
  • [10] Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-α (IFN-α), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC).: Dose-finding/phase II trial
    Buti, Sebastiano
    Lazzarelli, Silvia
    Simonelli, Cecilia
    Venturini, Silvia
    Spazzapan, Simon
    Lo Re, Giovanni
    Mattioli, Rodolfo
    Chiesa, Matteo Dalla
    Brighenti, Matteo
    Mazza, Giancarlo
    Passalacqua, Rodolfo
    ANNALS OF ONCOLOGY, 2007, 18 : 81 - 81
12345